Ketamine trialled for chronic post surgery pain

ADELAIDE: Hundreds of South Australians are being sought to join the world’s biggest medical trial looking at managing pain after surgery using ketamine — the ROCKet trial.

A new $100,000 grant from the The Hospital Research Foundation will help the program continue the work at the Royal Adelaide Hospital as well as other similar trials.

The ROCKet (Reduction of Chronic Postoperative Pain with Ketamine) lead investigator is Professor Philip Peyton from the University of Melbourne while the RAH trials are being run by Dr Thomas Painter and colleagues in the Department of Anaesthesia.

“Chronic post-surgical pain is one of the most common and debilitating post-operative complications,” Dr Painter said.

“This trial is focusing on reducing chronic post-surgical pain with ketamine, one of the only agents to have shown promise in this area.

“ROCKet is an Australian trial, devised and developed by Professor Philip Peyton in Melbourne and is being run by the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network.

“5000 patients worldwide are required for this trial and the RAH has shown in the past it can punch above its weight when contributing to this type of research. The results of this important and influential research are highly relevant to the people of South Australia who have so willingly agreed to be participants.”

Leanne Westwood of Campbelltown who had a total hip replacement last November is participating in the trial but doesn’t know if she was given the ketamine or a placebo.

“I had my first hip done in June 2016 and participated in a separate drug trial then so had no problem when asked to be part of this trial — I think it is really valuable research,” Ms Westwood, 61, who works at the Department for Energy and Mining, said.

“I’d encourage other people to participate in these sorts of things, if we don’t have human guinea pigs we won’t move forward in pain management.”

As well as the ROCKet project, two other trials developed by the ANZCA Clinical Trials Network are underway helped by South Australian volunteers and money from The Hospital Research Foundation.

More than 240 RAH patients have joined an 8880-patient global study called PADDI looking at the impact of dexamethasone — a drug commonly used to prevent nausea and vomiting after surgery — on surgical site infection.

Another 61 RAH patients are participating in the ITACS trial, in which intravenous iron is given for the treatment of anaemia before cardiac surgery, making up 25 per cent of the total 247 patients recruited so far.